CeNeS Pharmaceuticals plc (AIM: CEN) the Cambridge based biopharmaceutical company today announced that an important review of its lead product morphine-6-glucuronide (M6G) has been published in the international journal ‘Anesthesia and Analgesia’. The review, entitled ‘Morphine-6-Glucuronide: Morphine’s Successor for Postoperative Pain Relief?’ was written by the leading researcher, Professor Albert Dahan, and his team at the University of Leiden in the Netherlands. It indicates that currently available data demonstrate M6G’s efficacy as well as its improved safety profile when compared to morphine.
